Table 2 Weighted kappa, sensitivity and specificity along with the 95% CI for identification of AHD treatment between RAAS-generated clusters and AHD classification via scanning drug boxes

Normotensive

63(58–68)

46(39–52)

12(4–19)

77(68–85)

23(15–32)

0(0–4)

48(44–51)

70(66–73)

83(80–85)

Hypertensive

64(59–69)

44(37–50)

14(6–21)

82(73–89)

18(11–27)

0(0–4)

48(45–52)

69(65–72)

83(80–85)

Non-AHD

60(56–66)

41(34–48)

18(10–25)

91(84–96)

9(4–16)

0(0–4)

50(46–53)

68(64–71)

83(80–85)

Beta blockers

45(39–52)

22(17–28)

6(1–12)

89(81–94)

11(6–19)

0(0–4)

49(46–53)

49(46–53)

0(0–4)

ACEi

12(4–20)

45(39–52)

82(78–85)

24(16–34)

21(14–31)

55(44–65)

40(36–44)

69(66–73)

90(88–93)

ACEi + diuretics

25(19–31)

22(17–28)

78(75–82)

22(14–31)

11(6–19)

67(57–76)

40(36–43)

68(64–71)

92(90–94)

ARB

23(18–29)

74(69–80)

45(39–49)

27(18–36)

73(64–82)

0(0–4)

40(37–44)

83(81–85)

83(80–85)

ARB + diuretics

21(15–27)

51(46–55)

44(38–51)

31(23–41)

69(59–77)

0(0–4)

41(37–45)

76(73–79)

83(80–85)

Non-RAAS*

23(16–31)

60(53–65)

16(8–24)

85(81–88)

15(12–19)

0(0–1)

74(69–78)

56(51–61)

70(65–74)

ACEi or ACEi + diur**

12(4–22)

45(38–54)

82(79–86)

23(17–30)

16(11–22)

61(54–68)

34(30–38)

66(62–70)

100(99–100)

ARB or ARB + diur***

70(64–74)

41(34–48)

27(19–34)

29(23–36)

71(64–77)

0(0–2)

36(32–40)

84(81–87)

80(76–83)